Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of May 2024, specifically reporting a transaction notification dated May 03, 2024. The document serves as a disclosure of a securities transaction involving a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is a transaction-specific report rather than a financial performance statement.
| Metric | Value |
|---|---|
| Transaction Type | Sale of Ordinary Shares |
| Volume | 6,000 shares |
| Price per Share | £17.0167 |
| Total Value | £102,100.20 (Calculated) |
| Exchange | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses a reduction in the shareholding of a specific executive.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a mandatory regulatory disclosure of a specific share sale event.
Important Facts for Investors
- Executive Sale: Sally Jackson, SVP of Global Communications and CEO Office, sold 6,000 ordinary shares.
- Transaction Date: The sale occurred on May 01, 2024.
- Transaction Price: Shares were sold at £17.0167 each.
- Notification Type: This is an initial notification of the transaction.
- Scope Limitation: This filing does not contain quarterly or annual financial results.